IDEAYA Biosciences, Inc 8-K, filed Jun 16, 2020
IDEAYA Biosciences, Inc. (IDYA)
About this 8-K
IDEAYA Biosciences, Inc filed this 8-K on June 16, 2020, reporting on events of June 15, 2020.
Items reported
- Item 1.01: Entered into a material agreement
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 15, 2020
IDEAYA Biosciences, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware |
|
001-38915 |
|
47-4268251 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
7000 Shoreline Court, Suite 350
South San Francisco, California 94080
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (650) 443-6209
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
|
Common Stock, $0.0001 par value per share |
|
IDYA |
|
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 1.01 Entry into a Material Definitive Agreement.
On June 16, 2020, IDEAYA Biosciences, Inc. (the “Company”) announced that on June 15, 2020 it had entered into a Collaboration, Option and License Agreement (the “Agreement”) between the Company and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) Limited (“GSK”), pursuant to which the Company and GSK have entered into a strategic partnership and collaboration for the Company’s synthetic lethality programs targeting MAT2A, Pol Theta (“POLQ”), and Werner Helicase (“WRN”). The Agreement shall become effective upon the parties receiving Hart Scott Rodino Antitrust Improvements Act clearance (“HSR Clearance”) therefor.
Pursuant to the Agreement, GSK will pay the Company one hundred million dollars ($100,000,000) within ten business days of the effective date of the Agreement. GSK has committed to purchase in a private placement up to twenty million dollars ($20,000,000) of the Company’s common stock at a price per share equal to the public offering price per share paid in the Company’s next qualified underwritten public offering of its common stock.
MAT2A Program
For the MAT2A program, the Company will lead research and development through early clinical development. GSK has an exclusive option to obtain an exclusive license to continue development of and commercialize MAT2A products arising out of the MAT2A program (the “Option”), exercisable within a specified time period after the Company delivers to GSK a data package resulting from its conduct of a MAT2A Phase 1 monotherapy clinical trial. GSK’s exercise of the Option may be subject to HSR Clearance therefor at such time of exercise, and GSK must pay the Company an option exercise payment of fifty million dollars ($50,000,000).
GSK may initiate, or request the Company to initiate, a phase 1 combination clinical trial for a MAT2A product and GSK’s Type I PRMT inhibitor (GSK3368715) product (the “MAT2A Combination Trial”) prior to GSK’s’s exercise of the Option. The Company will be responsible for the costs of research and early clinical development activities that it conducts for the MAT2A program prior to GSK’s exercise of the Option (including during any interim waiting period for HSR Clearance for such Option exercise, if applicable), excluding the costs of conducting the MAT2A Combination Trial. GSK will be solely responsible for costs of the conduct of the MAT2A Combination Trial, except for supply of the MAT2A product therefor, to be provided by the Company at its own cost.
Subject to GSK’s exercise of the Option (and HSR Clearance thereof, if applicable), GSK will lead later stage global clinical development for the MAT2A program, with the Company responsible for twenty percent (20%) and GSK responsible for eighty percent (80%) of further development costs. The cost-sharing percentages shall be adjusted based on the actual ratio of U.S. to global profits for MAT2A products, as measured three and six years after global commercial launch thereof.
Subject to GSK’s exercise of the Option (and HSR Clearance thereof, if applicable), the Company will be eligible to receive future development and regulatory milestones of up to $465 million, and commercial milestones of up to $475 million, with respect to each MAT2A product. Additionally, the Company is entitled to receive fifty percent (50%) of U.S. net profits and tiered royalties on global non-U.S. net sales of MAT2A products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double digit percentages, subject to certain customary reductions. The Company has a right to opt-out of the fifty percent (50%) U.S. net profit share and corresponding development cost share for the MAT2A program, and would be eligible to receive tiered royalties on U.S. net sales of MAT2A products by GSK, its affiliates and their sublicensees at the same royalty rates as for global non-U.S. net sales thereafter, with potential positive economic adjustments based on the stage of the MAT2A program at the time of opt-out.
Pol Theta
Pursuant to the Agreement, GSK holds a global, exclusive license to develop and commercialize POLQ products arising out of the POLQ program. GSK and the Company will collaborate on ongoing preclinical research for the POLQ program, and GSK will lead clinical development for the POLQ program. GSK will be responsible for all research and development costs for the POLQ program, including those incurred by the Company.
The Company will be eligible to receive future development and regulatory milestones of up to $485 million, with respect to each POLQ product, including as applicable, for multiple POLQ products that target certain alternative protein domains or are based on alternative modalities. Additionally, the Company is eligible to receive up to $475 million of commercial milestones with respect to each POLQ product. The Company is also entitled to receive tiered royalties on global net sales of POLQ products by GSK, its affiliates and their sublicensees, subject to certain customary reductions.
Werner Helicase
Pursuant to the Agreement, GSK holds a global, exclusive license to develop and commercialize WRN products arising out of the WRN program. GSK and the Company will collaborate on ongoing preclinical research for the WRN program, and GSK will lead clinical development for the WRN program, with the Company responsible for twenty percent (20%) and GSK responsible for eighty
percent (80%) of such global research and development costs. The cost-sharing percentages shall be adjusted based on the actual ratio of U.S. to global profits for WRN products, as measured three and six years after global commercial launch thereof.
The Company will be eligible to receive future development milestones of up to $485 million, with respect to each WRN product, including as applicable, for multiple WRN products that are based on alternative modalities. Additionally, the Company is eligible to receive up to $475 million of commercial milestones with respect to each WRN product. The Company is also entitled to receive fifty percent (50%) of U.S. net profits and tiered royalties on global non-U.S. net sales of WRN products ranging from high single digit to sub-teen double digit percentages, subject to certain customary reductions. The Company has a right to opt-out of the fifty percent (50%) U.S. net profit share and corresponding research and development cost share for the WRN program, and would be eligible to receive tiered royalties on U.S. net sales of WRN products by GSK, its affiliates and their sublicensees at the same royalty rates as for global non-U.S. net sales thereafter, with potential positive economic adjustments based on the stage of the WRN program at the time of opt-out.
General
Under the terms of the Agreement, subject to certain exceptions and for an agreed period of time, the Company and GSK will not, themselves or through third parties, develop or commercialize other products whose primary and intended mechanism of action is the modulation of POLQ, WRN, or MAT2A (unless GSK does not exercise the Option or HSR Clearance does not occur with respect thereto, in which case such restriction shall cease to apply with respect to MAT2A). The Company and GSK will form a joint steering committee, joint development committees, and joint commercialization committees responsible for coordinating all activities under the Agreement.
GSK’s royalty obligations continue with respect to each country and each product until the later of (i) the date on which such product is no longer covered by certain intellectual property rights in such country and (ii) the 10th anniversary of the first commercial sale of such product in such country.
Each party has the right to sublicense its rights under the Agreement subject to certain conditions.
The Agreement will continue in effect on a product-by-product and country-by-country basis until the expiration of the obligation to make payments under the Agreement with respect to such product in each country, unless earlier terminated by either party pursuant to its terms. Either the Company or GSK may terminate the Agreement for the other party’s insolvency or certain uncured breaches. The Company may terminate the Agreement if GSK or any of its sublicensees or affiliates challenge certain patents of the Company. Gingko may terminate Agreement in its entirety or on a target-by-target basis upon certain notice to the Company.
The Agreement contains various representations, warranties, covenants, dispute resolution mechanisms, indemnities and other provisions customary for transactions of this nature.
The foregoing is only a summary description of the terms of the Agreement, does not purpose to be complete and is qualified in its entirety by reference to the Agreement, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ending June 30, 2020. The Company intends to omit certain confidential portions of the Agreement.
On June 16, 2020 the Company issued a press release announcing the Agreement. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 7.01. Regulation FD Disclosure.
On June 16, 2020, the Company began utilizing a new corporate presentation (the “Corporate Presentation”). A copy of the Corporate Presentation is attached hereto as Exhibit 99.2.
The information in this Item 7.01 and the attached Exhibit 99.2 are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing made by the Company under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
|
|
|
99.1 |
|
|
99.2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
IDEAYA BIOSCIENCES, INC. |
|
Date: June 16, 2020 |
By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer |
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology
|
‒ |
Partnership covers three IDEAYA Synthetic Lethality programs - MAT2A, Pol Theta and Werner Helicase, and will explore combinations between IDEAYA and GSK programs |
|
‒ |
IDEAYA will receive a $100 million upfront cash payment, and $20 million equity purchase of IDEAYA common stock in a direct private placement, and a potential $50 million cash option exercise fee for the MAT2A program. IDEAYA is also entitled to receive potential preclinical, clinical and sales milestones |
|
‒ |
IDEAYA will receive a 50% US profit share for the MAT2A and Werner Helicase programs and is responsible for 20% of global development costs for products being developed with GSK |
South San Francisco, CA, and London, United Kingdom, June 16, 2020 – IDEAYA Biosciences, Inc. (Nasdaq: IDYA) and GlaxoSmithKline plc (GSK) announce a strategic partnership in Synthetic Lethality, an emerging field in Oncology.
The strategic partnership includes IDEAYA’s Synthetic Lethality programs MAT2A, Pol Theta, and Werner Helicase programs, which are projected to reach clinical trials within the next three years. IDEAYA has solved the crystal structures for each of its MAT2A, Pol Theta and Werner Helicase programs, enabling structure-based drug design, and has demonstrated in vivo proof of concept in relevant animal models for its MAT2A and Pol Theta programs.
Synthetic Lethality is one of four core research focus areas for GSK in oncology. In synthetic lethality, cells tolerate the loss of single genes in isolation but not together in combination. When tumor suppressor genes are functionally lost in cancer, this mode of action can be used to exploit tumor-specific vulnerabilities through new medicines for patients with cancer.
“GSK is the ideal strategic partner for IDEAYA, as this partnership enables compelling potential combinations and the opportunity to build the industry leading Synthetic Lethality pipeline that targets molecularly defined populations in several major solid tumors, including potentially lung, prostate, breast, colorectal, and ovarian cancer,” said Yujiro S. Hata, Chief Executive Officer and President, IDEAYA Biosciences.
IDEAYA will lead the MAT2A program through early clinical development. IDEAYA is responsible for all costs of the MAT2A program prior to the GSK option exercise. Thereafter, IDEAYA is responsible for 20% of global development costs.
IDEAYA will receive a 50% US profit share and ex-US royalties for the MAT2A and Werner Helicase programs and is responsible for 20% of global development costs for licensed products being developed with GSK. IDEAYA will receive global royalties for the Pol Theta program, and GSK will cover all research, development, and commercialization costs. GSK will be responsible for all commercialization activities
and costs globally for licensed products. The collaboration agreement is conditional upon customary conditions including regulatory review by the appropriate regulatory agencies under the Hart-Scott-Rodino Act.
“GSK and IDEAYA have a vision to bring the next generation of innovative precision medicine therapies to patients utilizing the approach of Synthetic Lethality, and a highly complementary pipeline that has the potential to deliver transformative benefit for patients,” said Michael Dillon, Ph.D., Chief Scientific Officer, IDEAYA Biosciences.
IDEAYA Conference Call
At 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time today, IDEAYA's management will host a conference call and a simultaneous webcast presentation to discuss the transaction. The webcast presentation call can be accessed during the call by visiting the “Investors / News and Events / Presentation” section of IDEAYA’s website at www.ideayabio.com. Please connect to the website prior to the start of the call to allow adequate time for any software download that may be required. A replay of the webcast will be available through approximately fourteen days following the live presentation webcast.
About IDEAYA Biosciences
IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA’s approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies IDEAYA is developing. IDEAYA is applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets.
___________________
About GSK in Oncology
GSK is focused on maximising patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics, and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.
About GSK
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.
___________________
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to (i) the potential for cash payments related to MAT2A program option exercise and preclinical, clinical and sales milestones, (ii) the potential clinical combination of IDEAYA and GSK programs, (iii) the timing of IDEAYA’s Synthetic Lethality programs reaching clinical trials, (iv) the potential for an industry leading pipeline and potential solid tumor types to be addressed, and (v) the ability to deliver transformative value to patients. Such forward-looking statements involve substantial risks and uncertainties that could
cause IDEAYA’s preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes including Hart Scott Rodino Antitrust Improvements Act clearance, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA’s ability to successfully establish, protect and defend its intellectual property, the effects on IDEAYA’s business of the worldwide COVID-19 pandemic, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA’s recent Quarterly Report on Form 10-Q filed on May 12, 2020 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk Factors" in the company's Annual Report on Form 20-F for 2019 and any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
___________________
Investor and Media Contact
IDEAYA Biosciences
Paul Stone
Chief Financial Officer
investor@ideayabio.com
|
GSK enquiries: |
|
|
|
|
UK Media enquiries: |
Simon Steel |
+44 (0) 20 8047 5502 |
(London) |
|
|
Tim Foley |
+44 (0) 20 8047 5502 |
(London)
|
|
US Media enquiries: |
Kristen Neese |
+1 804 217 8147 |
(Philadelphia) |
|
|
Kathleen Quinn |
+1 202 603 5003 |
(Washington DC) |
|
|
|
|
|
|
Analyst/Investor enquiries: |
Sarah Elton-Farr |
+44 (0) 20 8047 5194 |
(London) |
|
|
Danielle Smith |
+44 (0) 20 8047 0932 |
(London) |
|
|
James Dodwell |
+44 (0) 20 8047 2406 |
(London) |
|
|
Jeff McLaughlin |
+1 215 751 7002 |
(Philadelphia) |
|
|
Frannie DeFranco |
+1 215 751 4855 |
(Philadelphia) |


Improving Lives Through Transformative Precision Medicines June 2020 Exhibit 99.2 Ideaya Biosciences Nasdaq: IDYA

Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of IDEAYA Biosciences, Inc. (the “Company”) and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparable terminology. All statements other than statements of historical fact could be deemed forward-looking, including any expectations regarding the Company’s target discovery platform or new target validation efforts as creating opportunities for research and development initiatives; any projections of financial information, market opportunities, cash runway or profitability; any statements about historical results that may suggest trends for the Company's business; any statements of the plans, strategies, and objectives of management for development programs or future operations; any statements about the timing of preclinical research, clinical development, regulatory filings, manufacturing or release of data; any statements of expectation or belief regarding future events, potential markets or market size, or technology developments; and any statements of assumptions underlying any of the items mentioned. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company's periodic filings with the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and any current and periodic reports filed thereafter. Except as required by law, the Company assumes no obligation and does not intend to update these forward-looking statements or to conform these statements to actual results or to changes in the Company's expectations. This presentation concerns anticipated products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). It is currently limited by Federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated. Safe Harbor Statement

Indication Biomarker Preclinical IND Phase 1 Phase 2 Status Collaboration IDE397 MAT2A Solid Tumors MTAP Targeting IND Q4 2020 PARG Solid Tumors Novel Biomarker In vivo Efficacy Polq Solid Tumors HRD In vivo Efficacy WRN Solid Tumors High-MSI Cell Activity DDT Solid Tumors Novel Biomarker Target Validation IDEAYA’s Precision Medicine Oncology Pipeline Building the Leading Synthetic Lethality Biotech Indication Biomarker Preclinical IND Phase 1 Phase 2 Status Collaboration IDE196 PKC inhibitor Solid Tumors Mono GNAQ/11 Ph2 Basket (Non-MUM) Enrolling Ph1 MUM Enrollment Complete Solid Tumors MEK Combo GNAQ/11 Target MEK Combo Start mid-2020 Clinical Trial Collaboration Kinase Pursuant to Pfizer Clinical Trial Collaboration and Supply Agreement PKC = protein kinase C, MUM = metastatic uveal melanoma Candidate Pipeline Research Pipeline Synthetic Lethality = Target program milestone through 2020 Pursuant to GSK Collaboration, Option and License Agreement: MAT2A and WRN: 50/50 US Profits + ex-US Royalties; Polq: Global Royalties Pursuant to CRUK Evaluation, Option and License Agreement, with ongoing Collaborative Research DDT = DNA Damage Target, WRN = Werner Helicase, Polq = DNA Polymerase Theta, HRD = homologous recombination deficiency, MSI = microsatellite instability (1) (1) (1) (2) (3) [LOGO]

Synthetic Lethality is an Emerging Field of Human Genetics Research and Precision Medicine Oncology Synthetic lethality occurs when the simultaneous perturbation of two genes results in cell death Synthetic lethal genetic interactions with tumor-specific mutations may be exploited to develop anticancer therapies Large-scale screening for cancer-gene-specific synthetic lethal candidates in human cells has progressed through advances in RNA interference and CRISPR-Cas9 editing Synthetic Lethality provides a powerful approach to discover the next generation of precision medicine therapies for molecularly-defined patient populations, including MTAP-deletion (~15% of all solid tumors), BRCA/HRD, and high-MSI (16% CRC) Reference: Charles Boone Nature Reviews Genetics, Vol. 18, 2017, Hieter, et al Mitochondria peroxisome metabolism & amino acid biosynthesis secretion & vesicle transport protein folding& glycosylation cell wall biosynthesis cell polarity & morphogenesis DNA replication & repair mitosis & segregation nuclear migration & protein degradation nuclear-cytoplasmic transport chromatin * transcription rna processing ribosome & translation nature reviews genetics

Fully-Integrated Target, Biomarker, and Drug Discovery Capabilities SL Target & Biomarker Discovery & Validation Dual CRISPR, CRISPR, siRNA Bioinformatics Genetically Engineered Models Drug Discovery Structure Based Drug Design Small Molecule Chemistry Protein Degrader Capabilities Potential 1st-in-class SL targets identified and validated, such as WRN SL biomarker discovery has delivered multiple patient population hypotheses 3 SL programs advanced to in vivo efficacy in target genetic settings Crystal structures for all four SL programs obtained to enable SBDD Potential best-in-class molecules discovered, including MAT2Ai, IDE397 Protein degraders advancing for selected targets Clinical Biomarker Genomics Tissue Based (IHC, IF) Liquid Biopsies IDEAYA Synthetic Lethality Platform [COMPANY LOGO]

IDEAYA Team and Scientific Advisory Board Scientific Thought Leaders in Synthetic Lethality and Precision Medicine Oncology IDEAYA Executives & R&D Leadership IDEAYA Scientific Advisory Board Yujiro Hata, M.B.A. President, Chief Executive Officer, Director Paul Stone, J.D. SVP, Chief Financial Officer Michael Dillon, Ph.D. SVP, Chief Scientific Officer Head of Research Mark Lackner, Ph.D. SVP, Head of Biology & Translational Sciences Mick O’Quigley, M.B.A. VP, Development Operations Paul Barsanti, Ph.D. VP, Head of Drug Discovery Jason Throne, J.D. VP, General Counsel Alan D’Andrea, M.D. IDEAYA SAB Chair Harvard Medical School, Professor Director, Center of DNA Damage and Repair, Dana Farber William Sellers, M.D. Broad Institute, Dana Farber, and Harvard, Professor Novartis, Former Head Oncology Research, SL Project Drive initiative Frank McCormick, Ph.D. UCSF, Professor and former Director, Helen Diller Cancer Center Former President AACR; Founder and CSO, Onyx Trey Ideker, Ph.D. UCSD, Professor, Co-Director Cancer Genomes & Networks Program, Research in Dual-CRISPR and SL interaction maps Jeffrey Hager, Ph.D. Former Chief Technology Officer, IDEAYA Elizabeth Swisher, M.D. University of Washington, Professor; Co-Leader, Breast and Ovarian Cancer Research Program, Seattle Cancer Care Alliance Principal Investigator on multiple PARP inhibitor trials Brian Daniels, M.D. Bristol Myers Squibb, Former SVP Global Development & Medical Affairs [COMPANY LOGO]

IDEAYA is Advancing the Next Generation of Synthetic Lethality Therapies PARP HRD/BRCA Lynparza (AZ) Zejula (GSK) Rubraca (Clovis) Talzenna (Pfizer) Today IDEAYA Synthetic Lethality Pipeline MAT2A MTAP-Deletion WRN High-MSI Target Discovery SL Targets Polq HRD PARG Replication Stress Novel Biomarker HRD = Homologous Recombination Deficiency, MSI = Microsatellite Instability

IDEAYA and GSK Strategic Partnership Landmark Partnership in Synthetic Lethality Validates IDEAYA Synthetic Lethality platform Enhances collective leadership in Synthetic Lethality Creates strategic combination opportunities Transformative Strategic Partnership Targets: MAT2A, Pol Theta and Werner Helicase Modalities: small molecule inhibitors & protein degraders $100M cash upfront $20M equity investment as direct private placement $50M option exercise fee for MAT2A 50/50 US profit share for MAT2A and Werner Helicase 20% global development cost share for US profit share Potential preclinical, clinical and sales milestones for each licensed product Royalties tiered high single-digit to sub-teen double digit % Key Partnership Terms DNA Polymerase Theta 50/50 US Profit Share and ex-US Royalties 20% global development cost share Cash payments upon preclinical, clinical and sales milestones WRN Helicase MAT2A Milestones and global royalties Cash payments upon preclinical, clinical and sales milestones IDEAYA leads early clinical; GSK option to exclusive license $50M Option Exercise Fee 50/50 US Profit Share and ex-US Royalties 20% global development cost share Cash payments upon clinical and sales milestones [COMPANY LOGO]

IDEAYA and GSK Strategic Partnership Partnership Enables Strategic Combinations IDE397 MAT2A GSK3368715 (Ph 1) Type I PRMT + Pol Theta Small Molecule Inhibitor or Protein Degrader Zejula™ PARP + Patient Population MTAP Deletion BRCA/HRD MAT2A + Type I PRMT Clinical Combination [COMPANY LOGO]

MTAP Deletion Prevalence MTAP-MAT2A Synthetic Lethality Biology MAT2A Inhibition is Synthetic Lethal with MTAP Deletion MTAP Deletion Prevalence ~15% of all Solid Tumors Data from The Cancer Genome Atlas in cBioPortal Cancer Type N MTAP Deletions (%) Glioblastoma 592 41 Mesothelioma 87 32 Esophageal 95 28 Bladder 411 26 Pancreatic 184 22 Melanoma 448 16 Lung Cancer (NSCLC) 1053 15 Head and Neck 523 14 Sarcoma 255 10 Esophagogastric 514 10 Diffuse Glioma 513 9 Breast 1084 3 Ovarian 585 3 Adrenocortical 92 3 Thymic 123 3 Hepatocellular 369 3 Renal non-clear cell 348 2 MAT2A MAT2A inhibitor MAT2A Methionine MAT2A is key enzyme that produces SAM in cells SAM PRMT5 MTAP Protein Methylation MTA MTA MTA MTAP deletion leads to MTA accumulation MTA accumulation partially inhibits PRMT5 Loss of methylation function of PRMT5 results in defects in RNA splicing, gene expression and genome integrity Inhibition of MAT2A results in reduction of SAM, starving PRMT5 of its substrate [COMPANY LOGO]

IDEAYA MAT2A Inhibitors Demonstrate Synthetic Lethality in MTAP-/- Cell Lines & PD Modulation of SAM Levels Structurally Enabled Lead Optimization Lead series includes multiple compounds with nM potency and >5x IC50 ratio in HCT116 wt vs MTAP -/- Synthetic Lethality in HCT116 Cell Line Consistent sensitivity across multiple MTAP-/- cell lines PD Modulation: SAM Levels in HCT116 Cell Line IDEAYA Data IDEAYA Data IDEAYA Data IDEAYA Data IDB proprietary MAT2Ai co-crystal structure (1.33Å) +17 high-resolution co-crystal structures [BAR CHART]

IDE397: MAT2A Development Candidate Nominated Targeting IND in Q4 2020 Significant reduction in tumor SAM levels with IDE397 at 5 mg/kg Tumor Pharmacodynamic Effect IDE397 (5 mg/kg) demonstrates greater tumor growth inhibition at 1/60th the dose vs AGI-25696 Published AG-270 preclinical dose is typically 200 mg/kg QD In Vivo Efficacy in HCT 116 MTAP-/- Model IDEAYA Data IDEAYA Data [BAR CHART]

IDB397 demonstrates efficacy at 1/30th of the dose of Agios MAT2A compound (see data) IDE397: MAT2A Development Candidate Nominated Differentiated Profile vs Agios Compounds IDEAYA Data Keystone Symposium 2017 Agios Data Days post implant 15 20 25 30 35 0 250 500 750 1,000 1,250 1,500 +/- S.E.M. 79% TGI P = 2e-31 Average Tumor Volume mm3) Vehicle MAT2Ai III 300 mg/kg IDE397 demonstrates greater in vivo efficacy at 5 to 10mg/kg More potent vs. AGI-25696 at 1/30th to 1/60th the dose in MTAP-deletion models IDE397 has not caused liver injury or increased unconjugated bilirubin Liver injury not observed in tox studies Not an inhibitor of UGT1A1 IDE397 has favorable physical properties, including solubility AG-270 observed non-linear exposure >200mg QD (GI absorption) IND-enabling studies initiated and targeting Q4 2020 IND IDE397 vs Agios Compounds Efficacy in Endogenous MTAP-/- Model (KP4) [BAR CHART]

IDE397 produced dose-dependent efficacy in a NSCLC model with regression (TGI >100%) at 30 mg/kg IDE397 Demonstrates Monotherapy Tumor Regression in an MTAP-Deleted Endogenous NSCLC Model In Vivo Endogenous NSCLC MTAP (-/-) PDX Model IDEAYA Data [BAR CHART]

Poly(ADP-ribose) glycohydrolase (PARG) plays a pivotal role in the regulation of DNA repair mechanisms PARG hydrolyzes the linkages to break down PAR chains, completing the cycle of DNA repair August 2019 Dysfunction of Poly(ADP-ribose) Glycohydrolase Induces a Synthetic Lethality Effect in Dual Specificity Phosphatase 22-deficient Lung Cancer Cells July 2019 Poly(ADP-ribose) Glycohydrolase Can be Effectively Targeted in Pancreatic Cancer PARG Synthetic Lethality Program Candidate Biomarkers: Replication Stress/HRD/Novel Biomarker Sasaki et al., Cancer Res, Aug 2019, 79:3851-3861; Jain et al, Cancer Res Jul 2019;79:4491-4502; Pillay et al., Cancer Cell Mar 2019, 35, 519–533 March 2019 DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-ribose) Glycohydrolase Inhibitors PARGi demonstrate cell viability effects in ovarian cell lines resistant to PARPi PARG & DNA Replication Vulnerabilities PARG Biology PARG Cancer Research Parp recognizes and binds to sites of damage parp catalyzes the synthesis of branched chains of poly (adp) ribose (par) nad+ nicotinamide+padpr par chains form a template for recruitment of dna damage repair proteins dna damage results in single strand breaks par chains are hydrolyzed by parg high grade serous ovarian cancer nad+nicotinamide parp parg par chains adp ribose free par parg inhibitor~20%brca1/2 mutant ~80% brca ½ WT ? robust dna replication +pargi replication vulnerability+pargi proliferation clonogenic potential ovcar3 kuramochi dmso pargi parpi

IDB-PARG Potency Biochemical IC50 7 nM PAR Foci cell EC50 50 nM Cell Viability EC50 510 nM Extensive research in PARG biology and chemistry Multiple collaborations ongoing to refine patient selection biomarker strategy IDEAYA has discovered potent PARG inhibitors SAR guided by structure-based drug design PARG Inhibitor In Vivo PD and Efficacy Data PARG Drug Discovery Program PARG Synthetic Lethality Program Drug Discovery on Potential 1st in Class DDR Synthetic Lethality Target IDEAYA PARG inhibitors demonstrate in vivo TGI in a model with a replication stress gene signature Significant tumor PAR accumulation observed in vivo IDEAYA Data IDEAYA Data [logo] [BAR CHART]

IDEAYA-proprietary Novel Synthetic Lethality Biomarker Targeting PARG development candidate in 2021 PARG Synthetic Lethality Program Monotherapy Tumor Regressions Observed in Multiple PDX Models IDB-PARG Demonstrates In Vivo Tumor Regressions in Multiple PDX Models IDEAYA Data [BAR CHART]

Project Drive: Werner is essential in MSI-high cancer cell lines Werner Syndrome Helicase is Required for the Survival of Cancer Cells with Microsatellite Instability IDEAYA Publication Discovery: multiple hit discovery campaigns using a range of screening formats and compound libraries completed Screening: robust suite of biochemical and biophysical assays to identify WRN inhibitors and differentiate false positives Structurally Enabled: structure of WRN helicase domain solved Lead Series: identified a lead series with <10 nM IC50 potency in a Werner helicase biochemical assay >10,000x potency improvement obtained through ongoing SAR Werner Helicase Drug Discovery Werner Helicase Biomarker WRN Werner Helicase Synthetic Lethality Program Candidate Biomarker: High-MSI (15% GI Cancers and 16% CRC) IDB-WRN1 ATPase IC50 = ~30 mM IDB-WRN2 ATPase IC50 < 10 nM IDEAYA Data Project Drive Cell Press, iScience, March 2019, Hager et al [COMPANY LOGO] [BAR CHART]

WRN Inhibitors Phenocopy Genetic Knockdown WRN Inhibitor Cellular PD and Viability WRN inhibitor WRN siRNA Werner Helicase Synthetic Lethality Program Candidate Biomarker: High-MSI (15% GI Cancers and 16% CRC) IDEAYA Data PD-marker: dose dependent increase of DNA damage marker gH2AX demonstrated at 48 hours Cell viability: MSI-high specific cell viability effect observed across multiple cell lines; no effect in MSS cell lines Target Milestone: In vivo efficacy data in 2020 IDEAYA Data [BAR CHART]

Polq Inhibitor In Vivo Activity Polq Inhibitor Cell Viability and Synergy PolQ Polq-1 as single agent and in combo with PARPi Polq-1 exhibits significant tumor growth inhibition in DLD1 BRCA2-/- xenograft model as a single agent Polq-1 and Olaparib combination demonstrates significant tumor growth inhibition (~95%) in DLD1 BRCA2-/- xenograft model Polq Synthetic Lethality Program Candidate Biomarker: BRCA/HRD TGI 95% IDEAYA Data IDEAYA Polq ATPase inhibitors show cell viability effects in DLD1 BRCA2-/- cell lines Polq-1 in vitro synergy with Olaparib in DLD1 BRCA2-/- cell lines IDEAYA Data [BAR CHART]

MEK Clinical Combination FPI targeted June 2020 Pfizer Clinical Trial Collaboration and Supply Agreement IDE196 + MEKi (binimetinib) Synergy Metastatic Uveal Melanoma (MUM) IDE196 + MEK Combo IDE196 IDE196 Phase 1/2 Clinical Program Summary IDE196 + MEK inhibitor (binimetinib) combination clinical trial Binimetinib drug supply available for approximately 40 patients Study goals are to identify tolerated combination dose and enhance clinical activity in MUM GNAQ/GNA11 Basket Trial: IDE196 Monotherapy AACR 2019 (Novartis): IDE196 BID Monotherapy in MUM (30 pts), ~73% Disease Control Rate & ~13% ORR IDEAYA sponsored: 51 MUM & 5 skin melanoma pts enrolled; additional Non-MUM patient enrollment ongoing Evaluate registrational path and potential partnership based on GNAQ/GNA11 basket trial and MEK clinical combo data in 2021/2022 PKC Inhibitor Targeting GNAQ/GNA11 Hotspot Mutation Tumors Ph2 Basket non-MUM (e.g. Skin Melanoma) Enrolling Q4 2020 Interim Data for IDE196 Monotherapy in MUM & Skin Melanoma GNAQ/GNA11 Basket Trial IDE196 Monotherapy [COMPANY LOGO]

AEB071 = 1st generation PKC inhibitor; MEK162 = binimetinib PKC + MEK Synergy MEL-202 Uveal Melanoma Cells Combo Rationale to Target PKC and MEK in the MAP-Kinase Pathway to Enhance Clinical Activity Combined PKC and MEK Synergistically Induced Tumor Regressions (92.1 Uveal Melanoma Xenograft) Biological Rationale for PKC + MEK combo IDE196 + Binimetinib Cell Viability Synergy IDEAYA Data Cancer Cell, May 2017, Chen et al Nature, Oncogene, 2014, Bastian et al [BAR CHART]

Indication Biomarker Preclinical IND Phase 1 Phase 2 Target Milestone through 2021 Collaboration IDE397 MAT2A Solid Tumors MTAP IND Q4 20 Phase 1 Initiation H1 2021 PARG Solid Tumors Novel Biomarker In vivo Efficacy 2020 Development Candidate 2021 Polq Solid Tumors HRD Development Candidate 2020 IND 2021 WRN Solid Tumors High-MSI In vivo Efficacy 2020 DDT Solid Tumors Novel Biomarker Chemistry Optimization IDEAYA’s Precision Medicine Oncology Pipeline Target Milestones through 2021 Indication Biomarker Preclinical IND Phase 1 Phase 2 Target Milestone through 2021 Collaboration IDE196 PKC inhibitor Solid Tumors Mono GNAQ/11 Ph2 Basket (Non-MUM) Enrolling Interim Data Q4 2020 Solid Tumors MEK Combo GNAQ/11 MEK Combo Enrollment Interim Data 2021/2022 Kinase Candidate Pipeline Research Pipeline Synthetic Lethality = Target program milestone through 2021 (1) (1) (1) (2) (3) Pursuant to GSK Collaboration, Option and License Agreement: MAT2A and WRN: 50/50 US Profits + ex-US Royalties; Polq: Global Royalties Pursuant to CRUK Evaluation, Option and License Agreement, with ongoing Collaborative Research DDT = DNA Damage Target, WRN = Werner Helicase, Polq = DNA Polymerase Theta, HRD = homologous recombination deficiency, MSI = microsatellite instability Pursuant to Pfizer Clinical Trial Collaboration and Supply Agreement PKC = protein kinase C, MUM = metastatic uveal melanoma [COMPANY LOGO]